DEA Blocks Anti-Cannabis Testimony in Trump Rescheduling Hearings

The Drug Enforcement Administration declined to provide testimony from agency officials at the request of Smart Approaches to Marijuana, a prohibitionist organization seeking to present anti-cannabis arguments during upcoming rescheduling hearings. The refusal represents a notable shift in DEA positioning as the Trump administration prepares to advance cannabis rescheduling proceedings that could fundamentally alter the regulatory landscape for the $30 billion legal cannabis market.

SAM requested testimony from DEA official Luli Akinfiresoye, who previously contributed to reports emphasizing cannabis-related harms. The agency's resistance to supporting prohibitionist testimony suggests internal recognition that rescheduling momentum has reached a critical threshold. This development carries substantial implications for multi-state operators like Curaleaf Holdings (CURA) and Green Thumb Industries (GTII), which face federal tax penalties under Section 280E that rescheduling would eliminate.

The DEA's position marks a departure from historical opposition to cannabis reform, potentially signaling bureaucratic acceptance of inevitable policy changes. Federal rescheduling would unlock institutional investment flows currently restricted by compliance concerns, while enabling interstate commerce that could consolidate the fragmented state-by-state market structure. Banking restrictions under current federal prohibition have forced operators to rely on expensive private capital, inflating operational costs across the sector.

Rescheduling hearings represent the most concrete federal reform progress in decades, with bipartisan support building momentum despite traditional law enforcement resistance. The cannabis industry has generated over $15 billion in state tax revenue since legalization began, creating powerful economic incentives for federal alignment with state policies. Major operators have positioned balance sheets for rapid expansion once federal barriers dissolve, with several maintaining cash reserves exceeding $100 million for acquisition opportunities.

The DEA's reluctance to amplify prohibitionist arguments during formal hearings indicates growing institutional consensus around reform inevitability. Cannabis stocks have rallied on rescheduling speculation throughout 2024, with the sector gaining over 40% during periods of heightened federal reform expectations. The agency's positioning suggests rescheduling proceedings will face less internal federal resistance than previously anticipated, accelerating timelines for meaningful regulatory changes that could unlock the industry's full market potential.